Dublin, Ireland, April 27, 2015 – Inflection Biosciences Ltd, a private company developing highly innovative treatments for cancer, today announced that it will be presenting at BioTrinity 2015. The presentation, to be given by Dr. Michael O’Neill, Director of Research and Development, will take place during the Oncology Session at 14.50 on Tuesday 12th May 2015.
BioTrinity is a leading European biopartnering and investment conference, bringing together R&D companies, big pharma, and investors. BioTrinity 2015 will be held at the Novotel London West, May 11th-13th, 2015.
About Inflection Biosciences
Inflection Biosciences Ltd, based in Dublin and London, is developing small molecule therapeutics for the treatment of cancer. The company's pipeline of highly innovative cancer treatments were licensed from the Spanish National Cancer Research Centre (CNIO). The pipeline comprises IBL-202 (PIM/PI3K inhibitor) and IBL-301 (PIM/PI3K/mTOR inhibitor), selected from a series of unique dual mechanism kinase inhibitors and the IBL-100 series (highly selective pan-PIM kinase inhibitors), currently in pre-clinical stages of development. Data generated to date suggests potential application in a range of haematological malignancies and treatment resistant solid tumours. Inflection Biosciences was named ‘Start-up Company of the Year’ at the 2014 Irish Pharma Awards. For more information please visit www.inflectionbio.com